1. Home
  2. GECC vs LONA Comparison

GECC vs LONA Comparison

Compare GECC & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

N/A

Current Price

$6.11

Market Cap

84.6M

Sector

Finance

ML Signal

N/A

Logo LeonaBio Inc. Common Stock

LONA

LeonaBio Inc. Common Stock

N/A

Current Price

$7.98

Market Cap

81.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GECC
LONA
Founded
2016
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.6M
81.5M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
GECC
LONA
Price
$6.11
$7.98
Analyst Decision
Buy
Buy
Analyst Count
2
1
Target Price
$10.75
$10.00
AVG Volume (30 Days)
49.8K
46.2K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
22.06%
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
N/A
N/A
Revenue This Year
$0.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$4.21
52 Week High
$11.45
$14.21

Technical Indicators

Market Signals
Indicator
GECC
LONA
Relative Strength Index (RSI) 62.23 50.77
Support Level $5.38 $6.86
Resistance Level $6.34 $8.66
Average True Range (ATR) 0.18 0.55
MACD 0.02 0.05
Stochastic Oscillator 80.56 35.63

Price Performance

Historical Comparison
GECC
LONA

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About LONA LeonaBio Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Share on Social Networks: